MCM9 and hypogonadism: In contrast to biallelic MCM8/MCM9 variant carriers, our current data suggest that the phenotype of monoallelic MCM8/MCM9 variant carriers may primarily be limited to hypogonadism, with no clear evidence of an increased cancer risk, which does not seem to justify cancer surveillance for these individuals.